Files and links (1)
Accepted (AM)Open Access (License Unspecified), Open
Journal article
Virological Basis for the Cure of Chronic Hepatitis B
ACS infectious diseases, v 5(5), pp 659-674
10 May 2019
PMID: 29893548
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Hepatitis B virus (HBV) has infected one-third of world population, and 240 million people are chronic carriers, to whom a curative therapy is still not available. Similar to other viruses, persistent HBV infection relies on the virus to exploit host cell functions to support its replication and efficiently evade host innate and adaptive antiviral immunity. Understanding HBV replication and concomitant host cell interactions is thus instrumental for development of therapeutics to disrupt the virus-host interactions critical for its persistence and cure chronic hepatitis B. Although the currently available cell culture systems of HBV infection are refractory to genome-wide high throughput screening of key host cellular factors essential for and/or regulating HBV replication, classic one-gene (or pathway)-at-a-time studies in the last several decades have already revealed many aspects of HBV-host interactions. An overview of the landscape of HBV-hepatocyte interaction indicates that, in addition to more tightly suppressing viral replication by directly targeting viral proteins, disruption of key viral-host cell interactions to eliminate or inactivate the covalently closed circular (ccc) DNA, the most stable HBV replication intermediate that exists as an episomal minichromosome in the nucleus of infected hepatocyte, is essential to achieve a functional cure of chronic hepatitis B. Moreover, therapeutic targeting of integrated HBV DNA and their transcripts may also be required to induce hepatitis B virus surface antigen (HBsAg) seroclearance and prevent liver carcinogenesis.
Metrics
Details
- Title
- Virological Basis for the Cure of Chronic Hepatitis B
- Creators
- Jin Hu - Baruch S. Blumberg InstituteJunjun Cheng - Baruch S. Blumberg InstituteLiudi Tang - Drexel UniversityZhanying Hu - Baruch S. Blumberg InstituteYue Luo - Second Xiangya Hospital of Central South UniversityYuhuan Li - Institute of Medicinal Biotechnology , Chinese Academy of Medical Science , 1 Tian-tan Xi-li , Beijing , 100050 , ChinaTianlun Zhou - Baruch S. Blumberg InstituteJinhong Chang - Baruch S. Blumberg InstituteJu-Tao Guo - Baruch S. Blumberg Institute
- Publication Details
- ACS infectious diseases, v 5(5), pp 659-674
- Publisher
- American Chemical Society; Washington, DC
- Grant note
- R01 AI113267 / NIAID NIH HHS
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Microbiology and Immunology
- Web of Science ID
- WOS:000468015100003
- Scopus ID
- 2-s2.0-85048707969
- Other Identifier
- 991019169418004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Chemistry, Medicinal
- Infectious Diseases